US Stocks: Viridian Shares Plunge 34% as Eye Disease Drug Disappoints on Efficacy Despite Trial Success

Why It Matters

The disappointing efficacy narrows Viridian’s revenue upside and intensifies competition in the niche TED market, influencing biotech valuations and investor sentiment.

Key Takeaways

• Shares fell 34% to $18.66 after trial results.
• Primary endpoint met, but efficacy below investor expectations.
• Four‑week dosing improved bulging 54% vs 18% placebo.
• Double‑vision improvement ambiguous, safety better with less frequent dosing.
• Marketing filing planned for Q1 2027, competing with Tepezza.

Pulse Analysis

Viridian Therapeutics’ recent data release underscores the volatility inherent in late‑stage biotech trials. While the elegrobart study achieved its primary goal of reducing proptosis, the magnitude of improvement—36% to 45% versus placebo—missed the 50%+ gains analysts had priced in. This gap between statistical success and market expectations triggered a sharp sell‑off, illustrating how investor sentiment can pivot on nuanced efficacy signals, especially when a competitor like Amgen’s Tepezza already commands the TED space.

Thyroid eye disease, an autoimmune condition affecting roughly 30,000 Americans annually, remains underserved beyond Tepezza, which requires intravenous infusion. Viridian’s home‑administered IGF‑1R therapy promises a more convenient delivery model and flexible pricing, potentially expanding the addressable market. However, the trial highlighted a trade‑off: the less‑frequent eight‑week dosing offered a cleaner safety profile, while the four‑week schedule delivered stronger efficacy. Balancing these attributes will be crucial for positioning elegrobart against Tepezza, especially as payers scrutinize cost‑effectiveness and real‑world outcomes.

From an investment perspective, the share plunge reflects broader concerns about commercial viability and pipeline risk. With a U.S. marketing application slated for the first quarter of 2027, Viridian must convince regulators and clinicians that its efficacy, even if modest, translates into meaningful patient benefit. Successful approval could restore momentum and validate the company’s broader TED portfolio, but any further setbacks may erode capital access and pressure the biotech’s valuation. Stakeholders will watch closely for FDA feedback and post‑approval data that could reshape the competitive landscape.